tetano
Editor, Senior Moderator
ACS Cent Sci. 2016 Oct 26;2(10):710-714. Epub 2016 Sep 29.
[h=1]Synthetic Mucus Nanobarriers for Identification of Glycan-Dependent Primary Influenza A Infection Inhibitors.[/h] Cohen M[SUP]1[/SUP], Senaati HP[SUP]1[/SUP], Fisher CJ[SUP]1[/SUP], Huang ML[SUP]1[/SUP], Gagneux P[SUP]1[/SUP], Godula K[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Current drugs against the influenza A virus (IAV) act by inhibiting viral neuraminidase (NA) enzymes responsible for the release of budding virions from sialoglycans on infected cells. Here, we describe an approach focused on a search for inhibitors that reinforce the protective functions of mucosal barriers that trap viruses en route to the target cells. We have generated mimetics of sialo-glycoproteins that insert into the viral envelope to provide a well-defined mucus-like environment encapsulating the virus. By introducing this barrier, which the virus must breach using its NA enzymes to infect a host cell, into a screening platform, we have been able to identify compounds that provide significant protection against IAV infection. This approach may facilitate the discovery of potent new IAV prophylactics among compounds with NA activities too weak to emerge from traditional drug screens.
PMID: 27800553 DOI: 10.1021/acscentsci.6b00191
[PubMed - in process]
[h=1]Synthetic Mucus Nanobarriers for Identification of Glycan-Dependent Primary Influenza A Infection Inhibitors.[/h] Cohen M[SUP]1[/SUP], Senaati HP[SUP]1[/SUP], Fisher CJ[SUP]1[/SUP], Huang ML[SUP]1[/SUP], Gagneux P[SUP]1[/SUP], Godula K[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Current drugs against the influenza A virus (IAV) act by inhibiting viral neuraminidase (NA) enzymes responsible for the release of budding virions from sialoglycans on infected cells. Here, we describe an approach focused on a search for inhibitors that reinforce the protective functions of mucosal barriers that trap viruses en route to the target cells. We have generated mimetics of sialo-glycoproteins that insert into the viral envelope to provide a well-defined mucus-like environment encapsulating the virus. By introducing this barrier, which the virus must breach using its NA enzymes to infect a host cell, into a screening platform, we have been able to identify compounds that provide significant protection against IAV infection. This approach may facilitate the discovery of potent new IAV prophylactics among compounds with NA activities too weak to emerge from traditional drug screens.
PMID: 27800553 DOI: 10.1021/acscentsci.6b00191
[PubMed - in process]